"Radiopharmaceuticals" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that are used in medicine as sources of radiation for radiotherapy and for diagnostic purposes. They have numerous uses in research and industry. (Martindale, The Extra Pharmacopoeia, 30th ed, p1161)
| Descriptor ID |
D019275
|
| MeSH Number(s) |
D27.505.259.843 D27.505.519.871 D27.720.470.410.650
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Radiopharmaceuticals".
Below are MeSH descriptors whose meaning is more specific than "Radiopharmaceuticals".
This graph shows the total number of publications written about "Radiopharmaceuticals" by people in this website by year, and whether "Radiopharmaceuticals" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1995 | 1 | 1 | 2 |
| 1996 | 1 | 1 | 2 |
| 1997 | 3 | 1 | 4 |
| 1998 | 5 | 2 | 7 |
| 1999 | 10 | 3 | 13 |
| 2000 | 13 | 9 | 22 |
| 2001 | 13 | 11 | 24 |
| 2002 | 8 | 14 | 22 |
| 2003 | 8 | 12 | 20 |
| 2004 | 9 | 24 | 33 |
| 2005 | 7 | 16 | 23 |
| 2006 | 12 | 16 | 28 |
| 2007 | 9 | 19 | 28 |
| 2008 | 3 | 26 | 29 |
| 2009 | 13 | 15 | 28 |
| 2010 | 10 | 17 | 27 |
| 2011 | 12 | 16 | 28 |
| 2012 | 4 | 16 | 20 |
| 2013 | 8 | 27 | 35 |
| 2014 | 9 | 38 | 47 |
| 2015 | 17 | 21 | 38 |
| 2016 | 8 | 16 | 24 |
| 2017 | 9 | 16 | 25 |
| 2018 | 6 | 10 | 16 |
| 2019 | 7 | 17 | 24 |
| 2020 | 4 | 15 | 19 |
| 2021 | 8 | 15 | 23 |
| 2022 | 1 | 13 | 14 |
| 2023 | 2 | 7 | 9 |
| 2024 | 6 | 6 | 12 |
To return to the timeline,
click here.
Below are the most recent publications written about "Radiopharmaceuticals" by people in Profiles.
-
SNMMI Clinical Trials Network Research Series for Technologists: An Introduction to Conducting Theranostic Clinical Trials. J Nucl Med Technol. 2024 Sep 05; 52(3):184-191.
-
True-Positive 18F-Flotufolastat Lesions in Patients with Prostate Cancer Recurrence with Baseline-Negative Conventional Imaging: Results from the Prospective, Phase 3, Multicenter SPOTLIGHT Study. J Nucl Med. 2024 Jul 01; 65(7):1080-1086.
-
Imageable Radioembolization Microspheres for Treatment of Unresectable Hepatocellular Carcinoma: Interim Results from a First-in-Human Trial. J Vasc Interv Radiol. 2024 Oct; 35(10):1464-1473.e1.
-
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024 Jun 29; 403(10446):2807-2817.
-
Thymic Imaging Pitfalls and Strategies for Optimized Diagnosis. Radiographics. 2024 05; 44(5):e230091.
-
Retrospective Dosimetry for Yttrium-90 Radioembolization with Resin Microspheres. J Vasc Interv Radiol. 2024 May; 35(5):709-711.
-
Enhancing NSCLC recurrence prediction with PET/CT habitat imaging, ctDNA, and integrative radiogenomics-blood insights. Nat Commun. 2024 Apr 11; 15(1):3152.
-
18F-FDG PET/CT and radiolabeled leukocyte SPECT/CT imaging for the evaluation of cardiovascular infection in the multimodality context: ASNC Imaging Indications (ASNC I2) Series Expert Consensus Recommendations from ASNC, AATS, ACC, AHA, ASE, EANM, HRS, IDSA, SCCT, SNMMI, and STS. Heart Rhythm. 2024 05; 21(5):e1-e29.
-
18F-FDG PET/CT and Radiolabeled Leukocyte SPECT/CT Imaging for the Evaluation of Cardiovascular Infection in the Multimodality Context: ASNC Imaging Indications (ASNC I2) Series Expert Consensus Recommendations From ASNC, AATS, ACC, AHA, ASE, EANM, HRS, IDSA, SCCT, SNMMI, and STS. JACC Cardiovasc Imaging. 2024 Jun; 17(6):669-701.
-
Focus on Uniformity, Not Dose: The Folly of Yttrium-90 Transarterial Radioembolization Dose-Escalation Studies. J Vasc Interv Radiol. 2024 Jun; 35(6):918-919.